Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label, Single Center, Uncontrolled Phase I/II Study Evaluating the Safety and Maximum Tolerated Dose of Daily Sorafenib Administered in Combination With Prolonged Temozolomide in Patients With Metastatic Melanoma

NCT00811759 is registered in ClinicalTrials.gov with Gustave Roussy, Cancer Campus, Grand Paris as lead sponsor.

NCT NCT00811759
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00811759 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label, Single Center, Uncontrolled Phase I/II Study Evaluating the Safety and Maximum Tolerated Dose of Daily Sorafenib Administered in Combination With Prolonged Temozolomide in Patients With Metastatic Melanoma
Lead sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Phase
Phase 1/2
Overall status
Unknown status
Start date
June 30, 2007
Completion date
Not reported
Enrollment
58 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma (skin)